30 results about "Allogeneic cell" patented technology

Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of RFX5, NLRC5, TAP2, β2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) to target tumor cells or other damaged cells in the patient and / or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.

The present invention relates to engineered immune cells expressing a chimeric antigen receptor (anti-mesothelin CAR) specific for mesothelin (MLSN) and their use in the treatment of solid tumors, particularly suitable for allogeneic cell immunotherapy.

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

The present invention provides methods and compositions for treating EBV-related disorders. [Solution] A method is provided for treating or preventing an EBV-related disease, disorder, or condition in a subject, comprising the steps of (a) administering to the subject a first population of allogeneic T cells that bind to or recognize a first epitope of an EBV antigen; and (b) administering to the subject a second population of allogeneic T cells that bind to or recognize a second epitope of the EBV antigen or a further EBV antigen, thereby treating or preventing the EBV-related disease, disorder, or condition in the subject.

The present disclosure provides methods and compositions for culturing and engineering of allogeneic B lineage cell populations.

This invention relates to the selective removal of activated T cells using a monovalent antibody or its antigen-binding fragment, which includes heavy chain variable regions and light chain variable regions of an antibody that specifically binds to CD3. In one embodiment of the present invention, the monovalent anti-CD3 antibody or its antigen-binding fragment is useful as a T cell removal agent or T cell immunosuppressant because it can selectively remove only activated T cells without affecting non-activated T cells. In particular, this invention is useful for the prevention or treatment of T cell-mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, as well as for the prevention of graft-versus-host disease (GVHD) side effects in allogeneic CAR-T cell therapy.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

Method for performing a bioprocess to obtain processed cell cultures, wherein the processed cell cultures are destined for autologous or allogenic cell therapy, wherein the bioprocess is performed on an integrated bioprocessing system, wherein the bioprocess comprises a sequence of processing steps, wherein the processing steps each comprise at least one operation, wherein the bioprocess system comprises a base structure and preconfigurable cartridges, wherein the bioprocess system performs operations of the bioprocess via an interaction of the base structure with the cartridges, wherein the cartridges and the base structure comprise matching standardized interfaces for an interaction of the base structure with the respective cartridge, wherein the bioprocess system performs at least two operations of the bioprocess inside at least two differently preconfigured cartridges by an interaction of the base structure with the cartridges via the same base structure interface and / or identical base structure interfaces and matching cartridge interfaces.

The invention relates to vaccination with immune-isolated cells producing immunomodulators. Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immune-isolated allogeneic cells that secrete an immunomodulator, such as GM-CSF (granulocyte-macrophage colony stimulating factor), and an antigen component (e.g., autologous tumor cells or infectious factors). Also provided herein are kits and pharmaceutical compositions containing the vaccine compositions and said products for use in methods of therapeutic or prophylactic vaccination against tumors or infectious factors.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The purpose of the present disclosure is to provide highly versatile, ready-to-deliver allogenic T cells for novel coronavirus infection, and a production method therefor. The present invention provides: a method for producing a cell population for the treatment and / or prevention of SARS-CoV-2 infection and including T cells or precursor T cells that express a human T cell receptor (TCR) specific to SARS-CoV-2, said method comprising a step for causing the expression of one or more human TCRs specific to SARS-CoV-2 in T cells or precursor T cells in vitro; and a cell population for the treatment and / or prevention of SARS-CoV-2 infection and produced via said method, said cell population comprising allogenically derived T cells or precursor T cells.

Disclosed herein is a pipeline to identify variable chains (VCR), which encompass T cell receptors (TCRs) and B cell receptors (BCRs), that recognize epitopes in their low affinity using a bioinformatic statistical method with 10× data that encompasses both preprocessing and identification of antigen-specific VCRs. Also disclosed are methods for treating subjects having viral infections or cancer, the methods comprising administering antibodies from B cells transduced with antigen-specific BCRs and / or modified allogenic T cells transduced with antigen-specific TCRs identified through use of the pipeline.

Provided herein are genetically engineered T cells containing a chimeric antigen receptor (CARs), and related methods and uses thereof in allogeneic cell therapy. In some embodiments, the T cells are genetically engineered with a CAR and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are cell compositions containing the engineered T cells, and related methods, kits and systems for producing the engineered T cells. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

Tubular prostheses are provided for use in the airways, upper digestive tract, and urinary tract. Each of these uses has its own set of biological specifications, based on what it must contain and discharge, as well as the physical and chemical pressures and loads to which it is subjected. The prostheses can be fabricated from allogeneic cells. Therefore, they can be fabricated and stored before an individual's personal need arises.

Compositions, methods, expression vectors and engineered immune cells for improving therapies that entail the administration of allogeneic cells to a patient. An immune cell, e.g., a T cell, modified to comprise and / or express FasL protein or a FasL protein derivative from, for example, an expression vector comprising a polynucleotide that encodes FasL protein or a FasL protein derivative, and to express FasR at a reduced level, and further modified to comprise and / or express an antigen binding protein e.g., a chimeric antigen receptor (CAR). An improved method of CAR T-cell therapy that comprises administering the improved immune cells, and compositions that comprise the improved immune cells. Methods of improving persistence of administered cells and reducing activation-induced cell death comprising administering the improved cells.

Disclosed herein are methods of selecting an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic T cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.

The invention discloses an InDel molecular marker library and application thereof. The InDel molecular marker library comprises one or more of 30 InDel loci selected from a human chromosome. The InDel molecular marker library provided by the invention can be applied to biological analysis of pharmacokinetics of clinical samples of allogeneic cell therapeutic drugs, can absolutely quantify the copy number of InDel targets in the samples without a standard substance, and is high in population coverage rate and high in sensitivity. An effective, reliable and universal analysis method is provided for clinical pharmacokinetic analysis of cells and gene therapy drugs without gene editing or only with limited gene editing, core molecular marker support is provided for accurate individual identification, and the method has wide application prospects.

In the various aspects and embodiments, the present disclosure provides cell populations or cell “banks” thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specific populations. In the various aspects and embodiments, the cell banks and progeny thereof maintain sufficient HLA Class I and HLA Class II functionalities, while facilitating patient matching to prevent or reduce graft versus host disease (GVHD) or graft rejection. The disclosure further provides methods for creating the cell banks by gene editing, and methods for cell therapy involving cells or tissues derived from the cell banks (including but not limited to hematopoietic stem cells, or “HSCs”, progenitors, or progenies thereof).

The present disclosure provides, among other things, methods for treating relapsed or refractory acute myeloid leukemia by administering to a subject in need thereof a therapeutically effective amount of an allogeneic composition comprising VDelta1+ (Vδ1+) gamma delta (γδ) T cells such that one or more symptoms or biomarkers is improved after treatment. The present disclosure also provides suitable doses of compositions comprising allogeneic Vδ1+gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, the Vδ1+gamma delta (γδ) T cells are untransduced.

The present invention relates generally to immunotherapy, in particular immunotherapy for treating cancer, infectious diseases or autoimmune diseases. More specifically, the invention relates to Mucosal-Associated Invariant T (MAIT) cells expressing Chimeric Antigen Receptors (CARs), wherein the MAIT cell is allogenic with respect to the subject to be treated.

The present invention relates to a use of a monovalent antibody or an antigen binding fragment thereof in the selective removal of activated T cells, the monovalent antibody or the antigen binding fragment thereof comprising a heavy chain variable region and a light chain variable region of an antibody specifically binding to CD3, the monovalent anti-CD3 antibody or the antigen binding fragment thereof according to one aspect of the present invention, and the use of the monovalent antibody or the antigen binding fragment thereof in the selective removal of activated T cells, the monovalent antibody or the antigen binding fragment thereof comprising a heavy chain variable region and a light chain variable region of an antibody specifically binding to CD3, and the use of the monovalent antibody or the antigen binding fragment thereof in the selective removal of activated T cells. According to the present invention, only activated T cells can be selectively cleared without affecting non-activated T cells, such that the T cell scavenger can be effectively used as a T cell scavenger or a T cell immunosuppressive agent; according to the present invention, it is possible to effectively prevent or treat T-cell mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, or to prevent the side effects of graft-versus-host diseases (GVHD) in an allogeneic CAR-T cell therapy, or to treat T-cell mediated autoimmune diseases, graft-versus-host diseases, or organ transplant rejection, or to prevent the side effects of the graft-versus-host diseases (GVHD) in the allogeneic CAR-T cell therapy.

The present disclosure relates to compositions comprising allogeneic invariant natural killer T (iNKT) cells, including allogeneic iNKT cell adjuvants, and methods of using the compositions comprising the iNKT cells for treatment of diseases and conditions, including cancer.

Provided herein are, inter alia, are methods for producing expanded population of mycophenolate resistant CAR-T cells. The methods provided herein are, inter alia, useful for producing an expanded population of mycophenolate resistant CAR-T cells for the treatment of cancer. Also provided herein are, inter alia, compositions including the expanded population of mycophenolate resistant CAR-T cells produced by the methods described herein.

Disclosed are engineered cells and use thereof. Compared with the wild type, the engineered cells lack or reduce the expression of the HLA-A protein and / or the HLA-B protein. The disclosed engineered cells can significantly reduce the immune rejection response after artificial blood cell infusion, and significantly improve the implantation rate and long-term reconstruction ability in vivo. The cells will significantly expand the use of existing cord blood and bone marrow donor libraries, reduce the need to recruit a large number of donors to match receptors, and increase the probability of HLA matching donors, thereby expanding the infusion of clinical-grade allogeneic cells. As a source of universal cells, the engineered cells can enable HLA-matching off-the-shelf cell therapy, showing great promise in the area of clinical transplantation treatment.

The present disclosure provides methods and compositions for culturing and engineering of allogeneic B lineage cell populations.

Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR− cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy. Provided herein are methods that increase the efficiency of depleting TCR+ cells from a population of cells in order to significantly reduce any residual levels of TCR+ cells present in cell populations in which expression of endogenous TCR has been reduced or eliminated. Associated kits and cell populations are also provided.

This disclosure provides, in particular, a method for treating relapsed or refractory acute myeloid leukemia, wherein one or more symptoms or biomarkers are improved after treatment by administering a therapeutically effective amount of an allogeneic composition containing Vδ1+ (Vδ1+) gamma delta (γδ) T cells to a subject in need. This disclosure also provides appropriate doses of a composition containing allogeneic Vδ1+ gamma delta (γδ) T cells for administration to a subject suffering from relapsed or refractory AML. In some embodiments, these Vδ1+ gamma delta (γδ) T cells are not transduced.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The present invention provides an engineered cell and application thereof. Compared with a wild type cell, the engineered cell lacks or reduces the expression of HLA-A protein and HLA-B protein. The engineered cell disclosed by the present invention can significantly reduce immune rejection response after human hematopoietic cell infusion, and the implantation rate and long-term reconstruction ability in vivo are significantly improved. The cell will significantly expand the use of existing umbilical cord blood and bone marrow donor banks, reduce the need to recruit a large number of donors to match receptors and increase the probability of HLA matching donors, thereby expanding the infusion of clinical-grade allogeneic cells. The engineered cell, as the source of a universal cell, can achieve an HLA matched off-the-shelf cell therapy and has an important clinical transplant transplantation therapy prospect.